BSX · Boston Scientific Corp
United States · RS rating 33 · As of 2026-11-03
| Price | 43.50 USD |
|---|---|
| 1-day change | -1.9% |
| RS rating (overall / 1M / 3M / 12M) | 33 / 65 / 48 / 18 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 10 / 29 |
| Industry group (rank) | Medical-Products (106) |
| EPS growth Q/Q | -11.8% |
| Sales growth Q/Q | +4.4% |
| Distance from 52-week high | +58.6% |
| Market cap (USD) | $97.6B |